摘要
目的研究福辛普利对糖尿病大鼠胰腺肾素血管紧张肽醛固酮系统(RAAS)及胰岛功能的影响。方法链脲佐菌素(STZ)联合高脂高糖饮食制作糖尿病大鼠动物模型,造模成功者随机分为模型组和用药组,每组7只;同时随机选取7只正常大鼠作为对照组。用药组在造模成功后给予福辛普利500mg·kg-1·d-1灌胃,其余2组予等量蒸馏水代替。8wk后测定血糖、血胰岛素和胰腺血管紧张肽Ⅰ(AngⅠ)、血管紧张肽Ⅱ(AngⅡ)和醛固酮(ALD)含量,免疫组化方法观察胰腺组织胰岛素的表达。结果与模型组相比,用药组大鼠体重明显增长,血胰岛素水平及β细胞分泌指数上升,空腹血糖明显下降,胰腺组织中AngⅠ、AngⅡ含量明显下降(P<0.05),ALD含量无显著差异。用药组胰腺各分泌细胞排列、分布趋于均匀,胰岛素表达较模型组增多。结论福辛普利可降低胰腺AngⅠ、AngⅡ的含量,改善胰岛功能。
AIM To study the effects of fosinopril on renin-angiotensin-aldosterone system (RAAS) and pancreatic islet function in diabetic rats. METHODS Rat models of type 2 diabetes mellitus were induced by streptozotocin combined with high fat and high sucrose diet, the successful models were randomly divided into model group and fosinopril treated group (n = 7); while 7 normal rats were randomly chosen as control group. After the model was successfully constructed, rats in the control group and model group were peffused with distilled water, and rats in fosinopril treated group was administered with fosinopril (500 mg·kg^-1·d^-1) for 8 weeks. The fasting blood glucose (FBG), fasting insuline, angiotensin I (Ang I ), angiotensin Ⅱ (Ang Ⅱ ) and aldosterone (ALD) were tested, and the expression of insulin was observed by immunohistochemistry method. RESULTS Compared with the model group, the weight, blood insulin level, and the secretion index of β cellsincreased remarkably, and FBG, the content of Ang I and Ang Ⅱ decreased significantly in fosinopril treated group (P 〈 0.05). There was no significant difference of ALD between two groups. The immunohistochemistry method showed that the organization and distribution of secretory cells were uniform in the fosinopril treated group, and the expression of insulin in the fosinopril treated group was more than that in the model group. CONCLUSION Fosinopril could decrease the concentration of Ang I, Ang Ⅱ, and improve the pancreas function.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2009年第7期526-529,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
糖尿病
胰腺
胰岛
福辛普利
肾素血管紧张素醛固酮系统
diabetes mellitus
pancreas
islets of langerhans
fosinopril
renin-angiotensin-aldosterone system